Navigation Links
Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Date:5/20/2013

ewMet has long-term glucose lowering benefits with a tolerability and safety profile that is superior to currently marketed metformin, the #1 diabetes product in the world. This would allow many more patients with Type 2 diabetes to enjoy the full benefit of metformin's active ingredient."

In Phase 2a studies in patients with Type 2 diabetes, NewMet reduced fasting plasma glucose to a similar extent as generic metformin but had improved tolerability.  Pharmacokinetic/pharmacodynamic studies have shown that glucose lowering and augmented release of the gut hormones peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were similar to generic metformin despite NewMet's dramatically lower plasma exposure.

By targeting the lower gut and reducing systemic absorption, NewMet may be appropriate for the large population of renally impaired patients with Type 2 diabetes that are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening result of metformin build-up in the blood. There are few safe and sufficiently effective oral agents to treat Type 2 diabetes patients with renal impairment. Elcelyx plans to initiate a pharmacokinetics/pharmacodynamics study of NewMet in Type 2 diabetes patients with mild, moderate and severe renal impairment. The study is expected to begin this summer.

NewMet is also an ideal candidate for fixed-dosed combinations with other oral antidiabetic agents, such as DPP4is and SGLT2is, because it can deliver a maximally effective dose of metformin in a single once-daily tablet and does not require titration.

About Elcelyx Therapeutics
Elcelyx Therapeutics develops pharmaceutical and consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) platform. Pharmaceutical product candidate NewMet™ is being developed for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and FARMINGTON, Conn. , ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of Series E warrants to purchase 21,917,808 ... warrants to purchase 2,191,781 shares of its common ...
(Date:7/6/2015)... , July 6, 2015  Impax Laboratories, Inc. ... Hsu , Ph.D. has resigned from the Company,s Board ... Dr. Hsu was a co-founder of Impax in 1995 ... Officer from October 2006 until April 2014. ... Wilkinson , Impax,s President and Chief Executive Officer stated, ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
Breaking Medicine Technology:Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
... production, increasing blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. ... Hypertension Research reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark ... oxide,(NO) production which leads to an increase in blood flow and ...
... Developed Through Joint Venture Between Bristol-Myers Squibb, ... Its Kind in HIV Treatment -, PRINCETON, ... Bristol-Myers Squibb Company (NYSE: BMY ) and ... that Health Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:7/5/2015)... ... ... Women's Excellence in Wellness, powered by Movestrong announces parent/child fitness classes ... families that want their children to stay active as well as spend time with ... place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s Excellence in Wellness, powered by ...
(Date:7/4/2015)... ... 04, 2015 , ... Earlier in 2015, on Feb. 26, ... member survey , detailing the most common plastic surgery and minimally invasive cosmetic ... data down into charts detailing demographic trends and regional preferences. With a focus ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, ... retained to lead a national president recruitment for Regional Care, Inc. ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is ... Room , the largest network of independent freestanding emergency rooms in the United States. ... of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... from Japan specifically for event -, MCLEAN, ... robotic baby,harp seal more effective than real, live ... with dementia and other aging-related,illnesses?, Come find ... when Vinson Hall,Retirement Community (VHRC) in McLean, Va., ...
... Study Published in Journal of Occupational and Environmental Medicine, Investigates ... ... Resource Utilization, PHILADELPHIA, May 12 High ... total,healthcare costs, according to a new study published this month ...
... (SPECT), researchers in The Netherlands were able to ... with generalized social anxiety disorder (also known as ... cause for the dysfunction. , The study, which ... Journal of Nuclear Medicine, compared densities of elements ...
... diet to look more attractive. Fish diet to avoid ... and getting eaten as a result. , That is the ... researchers from the ARC Centre of Excellence for Coral Reef ... Current Biology. , The same team who recently revealed fish ...
... May 12 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... operating room, today announced financial results for the first,quarter ended ... dollar amounts are expressed in US dollars., Q1 ... 14 new SPY systems installed, 22% increase ...
... the following preliminary,unaudited net sales results for the month of April 2008 by segment:, , ... (Preliminary and Unaudited) ... MONTH OF APRIL ... ...
Cached Medicine News:Health News:Paro, the World's Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5Health News:Are anxiety disorders all in the mind? 2Health News:Fish diet to avoid fights 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 3Health News:Novadaq Reports Financial Results for the First Quarter of 2008 4Health News:Novadaq Reports Financial Results for the First Quarter of 2008 5Health News:Novadaq Reports Financial Results for the First Quarter of 2008 6Health News:Novadaq Reports Financial Results for the First Quarter of 2008 7Health News:Novadaq Reports Financial Results for the First Quarter of 2008 8Health News:Novadaq Reports Financial Results for the First Quarter of 2008 9Health News:Novadaq Reports Financial Results for the First Quarter of 2008 10Health News:Novadaq Reports Financial Results for the First Quarter of 2008 11Health News:NBTY Announces Preliminary Unaudited Net Sales Results for April 2008 2
... excellent classical blood film stain used ... marrow. Erythrocytes stain pink to buff ... pale pink. Leukocyte nuclear chromatin stains ... "ground glass" blue and lymphocyte cytoplasm ...
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: